ATLANTA, GA--(MARKET WIRE)--Mar 24, 2008 -- MIV Therapeutics, Inc. (OTC BB:MIVT.OB - News) (Frankfurt:MIV.F - News) (“the Company”), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announces preliminary nine-month data from the first-in-man MIVT Pilot Trial that evaluates the safety and efficacy of MIVT’s polymer-free nanoscale microporous hydroxyapatite drug-eluting stent will be presented at the 57th Annual Scientific Sessions of the American College of Cardiology in Chicago, Ill.
Jose Costa, M.D. of Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, will discuss these preliminary data in a moderated poster titled, “Preliminary Results of the Hydroxyapatite Non-Polymer-Based Sirolimus-Eluting Stent for the Treatment of Single de novo Coronary Lesions: A First-in-Human Analysis of a Third-Generation Drug-Eluting Stent System.”
Dr. Costa’s presentation will take place on Sunday, March 30, 2008 at 1:18 p.m. CDT in Room S103a of the McCormick Place Convention Center as part of session 2902 titled Moderated Poster Session II.
On Monday, March 31, 2008 at 10:45 a.m. CDT in Room S102 as part of session 2621 titled Drug-Eluting Stents 2008 Principal Investigator of the study Alexandre’ Abizaid, M.D., Ph.D, Chief of Coronary Intervention of Institute Dante Pazzanese of Cardiology in Sao Paulo, Brazil, will discuss this data further.
“Our goal is to restore confidence in drug-eluting stents with Vestasync by combining the safety profile of bare metal stents with the efficacy of a drug-eluting stents,” said Dr. Mark Landy, President and CEO of MIV Therapeutics. “Presenting this data at the world’s premier cardiovascular meeting is important recognition of the significance of our proprietary technology and we look forward to advancing the Vestasync program with subsequent trials.”
About the American College of Cardiology
The American College of Cardiology is leading the way to optimal cardiovascular care and disease prevention. The College is a 34,000-member nonprofit medical society and bestows the credential Fellow of the American College of Cardiology upon physicians who meet its stringent qualifications. The College is a leader in the formulation of health policy, standards and guidelines, and is a staunch supporter of cardiovascular research. The ACC provides professional education and operates national registries for the measurement and improvement of quality care.
About MIV Therapeutics
MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents, as well as for a broad range of other implantable medical devices. The Company’s ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. This coating platform is derived from hydroxyapatite (HAp), an organic material that has demonstrated excellent in vivo safety and biocompatibility. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth, and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company’s novel polymer-free drug-eluting technologies based on HAp could also provide an attractive alternative to current polymer-based drug-eluting coatings on the stent market, which have been associated with undesirable effects. The Company’s drug-eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIV Therapeutics has a Collaborative Research Agreement with the University of British Columbia and has received a government grant for its research program on the “Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents,” under the National Research Council-Industrial Research Assistance Program. Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization. MIV’s intellectual property portfolio includes patents held by the University of British Columbia and exclusively licensed to MIV. Key patent applications filed simultaneously in various countries around the world further protect the commercial exclusivity of MIV’s inventions in the global marketplace. For more information, please visit www.mivtherapeutics.com.
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as “proposed,” “expected,” “believe,” “will,” “breakthrough,” “significant,” “indicated,” “feel,” “revolutionary,” “should,” “ideal,” “extremely” and “excited.” These statements are made under “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties including, without limitation, the closing of the Share Purchase Agreement, the ability of the Company to raise sufficient funding and to continue to develop its various business interests as presently contemplated. See the Company’s filings with the Securities and Exchange Commission including, without limitation, the Company’s recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Contact: Contacts For Investor Inquiries: Anthony L. Huston Director of Investor Relations MIV Therapeutics, Inc. (604) 301-9545, x14 ahuston@mivtherapeutics.com investor@mivtherapeutics.com
Kim Sutton Golodetzk golodetz@lhai.com Emmanuelle Ferrer eferrer@lhai.com Lippert/Heilshorn & Associates, Inc. (212) 838-3777
For Media Inquiries: Michele Fox / Cassie Wallace Schwartz Communications 781-684-0770 miv@schwartz-pr.com
Source: MIV Therapeutics, Inc.
